Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Oncotarget published "Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells" which reported that to ascertain phenotypical differences between these two distinct culture conditions, these authors carried out a comparative proteomic analysis of a membrane fraction obtained from 3D- and 2D-cultured NSCLC model cell line NCI-H23.

29 Sep 2021

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Oncotarget published "Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma" which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.

29 Sep 2021

Human coronavirus replicates in bats without using the spike protein

Researchers in Singapore have conducted a study showing active replication of a human coronavirus in bats that occurred without the viral spike protein binding to host cell receptors.

28 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Scientists create new compliance-based model for SARS-CoV-2 transmission

Researchers from Utrecht University have been investigating the interactions between compliance social distance measurements, infection, and vaccination coverage in order to inform public health policy further. A research paper covering their work is available on the medRxiv* preprint server.

28 Sep 2021

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Researchers from the University of Oxford and the University of Warwick have collaborated to develop a method to better understand and evaluate these pleiomorphisms.

28 Sep 2021

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

It has been demonstrated in recent studies that there is a significant breadth of emerging autoreactivity associated with severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. More specifically, researchers from Emory University have identified a relaxation of peripheral tolerance within early antibody secretion cells that arise in individuals infected with SARS-CoV-2, as important drivers of those responses.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

A version of SARS-CoV-2, the virus that causes COVID-19 disease, has been successfully modified to glow brightly in cells and animal tissues, providing a real-time way to track the spread and intensity of viral infection as it happens in animal models, researchers at Texas Biomedical Research Institute report in the journal The Proceedings of the National Academy of Sciences.

27 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

A new study explores the real-world efficacy of monoclonal antibodies against COVID-19 in averting severe disease.

27 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

New research discusses the development of soluble prefusion-stabilized spike trimers (CoV2 preS dTM) comprising adjuvant AS03.

27 Sep 2021

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

A new review article investigates the clinical and viral characteristics, pathogenesis, as well as human genetic basis associated with COVID-19.

27 Sep 2021

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

Despite the advent of numerous vaccines and the discovery of passive monoclonal antibodies for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there remains an urgent need for definitive therapies for coronavirus disease-2019 (COVID-19) patients.

27 Sep 2021

mRNA COVID vaccines prove effective in the elderly

Coronavirus disease 2019 (COVID-19) proved extremely difficult to control once it entered a country – while there were a few success stories such as New Zealand, most countries ended up resorting to lengthy and economically painful lockdowns, among other restriction measures.

27 Sep 2021

WHO urges to address the high price and limited production of antibody combination for COVID-19

The World Health Organization (WHO) welcomes the addition of another therapeutic to the world's arsenal against COVID-19, but urges producing companies and governments to address the high price and limited production of the Regeneron antibody combination and ensure safe and appropriate handling of the medicine.

27 Sep 2021

Antibody News and Research

Further Reading

New analysis reveals distinct differences between molecular profiles of 3D and 2D cultured cells

Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

Human coronavirus replicates in bats without using the spike protein

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Scientists create new compliance-based model for SARS-CoV-2 transmission

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

New 'reporter viruses' make it easier to observe SARS-CoV-2 in real time

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Monoclonal antibodies may reduce hospital stay, but not mortality in COVID-19

Chronic COVID-19 and divergent variants of SARS-CoV-2

Trial of Sanofi/GSK SARS-CoV-2 vaccine boosters against variants in non-human primates

Review of COVID-19 clinical and viral characteristics, pathogenesis, and genetics

B cell activating anti-CD73 antibody for the immunotherapy of COVID-19

mRNA COVID vaccines prove effective in the elderly

WHO urges to address the high price and limited production of antibody combination for COVID-19

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo